Patients
DLBCL
A total of 124 patients were enrolled; 17 patients were enrolled in the dose escalation phase and received mivavotinib at the following doses: 60 mg QD (Of the patients with DLBCL, 12 were enrolled during dose escalation, 41 were enrolled to the first expansion cohort, and 36 were enrolled to the second expansion cohort. By data cut-off, treatment had been discontinued in all 124 patients. Patient disposition is summarized in 